pd 98059 and tigapotide

pd 98059 has been researched along with tigapotide in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Annabi, B; Béliveau, R; Bouzeghrane, M; Currie, JC; Daigneault, L; Dulude, H; Garde, S; Panchal, C; Rabbani, SA; Wu, JJ	1

Other Studies

1 other study(ies) available for pd 98059 and tigapotide

Article	Year
Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling. Anti-cancer drugs, 2006, Volume: 17, Issue:4 Topics: Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; ELAV Proteins; ELAV-Like Protein 1; Flavonoids; Humans; Laminin; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Oligopeptides; Peptide Fragments; Prostatic Neoplasms; Prostatic Secretory Proteins; Protein Binding; Protein Serine-Threonine Kinases; Receptors, Laminin; RNA-Binding Proteins; Signal Transduction	2006

Article

Year

Inhibition of MMP-9 secretion by the anti-metastatic PSP94-derived peptide PCK3145 requires cell surface laminin receptor signaling.

Anti-cancer drugs, 2006, Volume: 17, Issue:4

Topics: Antigens, Surface; Bone Neoplasms; Cell Line, Tumor; ELAV Proteins; ELAV-Like Protein 1; Flavonoids; Humans; Laminin; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Oligopeptides; Peptide Fragments; Prostatic Neoplasms; Prostatic Secretory Proteins; Protein Binding; Protein Serine-Threonine Kinases; Receptors, Laminin; RNA-Binding Proteins; Signal Transduction

2006